Gilead Sciences Inc (GILD)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 78.26% | 100.00% | 79.26% | 75.82% | 81.48% |
| Operating profit margin | 5.78% | 28.05% | 26.87% | 27.12% | 28.47% |
| Pretax margin | 2.40% | 25.30% | 21.31% | 30.32% | 6.76% |
| Net profit margin | 1.67% | 20.89% | 16.83% | 22.80% | 0.36% |
Based on the provided data, Gilead Sciences Inc's profitability ratios have varied over the years.
1. Gross Profit Margin:
- Gilead Sciences Inc's gross profit margin has fluctuated, starting at a high of 81.48% in December 2020, decreasing to 75.82% in December 2021, then increasing to 79.26% by December 2022, and reaching 100.00% in December 2023, before declining to 78.26% in December 2024.
2. Operating Profit Margin:
- The company's operating profit margin has shown a downward trend, decreasing from 28.47% in December 2020 to 27.12% in December 2021 and further declining to 5.78% by December 2024.
3. PreTax Margin:
- Gilead Sciences Inc's pretax margin experienced significant variability, with a notable increase from 6.76% in December 2020 to 30.32% in December 2021, followed by fluctuations to 21.31% in December 2022, 25.30% in December 2023, and a sharp drop to 2.40% in December 2024.
4. Net Profit Margin:
- The net profit margin of Gilead Sciences Inc also demonstrated fluctuations, starting at a low of 0.36% in December 2020, then significantly increasing to 22.80% in December 2021, and further varying to 16.83% in December 2022, 20.89% in December 2023, and decreasing to 1.67% by December 2024.
Overall, Gilead Sciences Inc has experienced changes in its profitability margins over the years, reflecting variations in the company's efficiency in generating profits relative to its revenue and costs. Investors and stakeholders may need to closely monitor these trends to assess the company's financial performance and sustainability.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 2.82% | 12.24% | 11.60% | 10.90% | 10.28% |
| Return on assets (ROA) | 0.81% | 9.12% | 7.27% | 9.16% | 0.13% |
| Return on total capital | 8.62% | 33.31% | 31.82% | 44.05% | 14.56% |
| Return on equity (ROE) | 2.48% | 24.81% | 21.65% | 29.55% | 0.49% |
Based on the provided data for Gilead Sciences Inc profitability ratios, we can observe the following trends:
1. Operating return on assets (Operating ROA) has shown consistent improvement over the years, starting at 10.28% on December 31, 2020 and increasing to 12.24% by December 31, 2023. However, there was a notable decline to 2.82% by December 31, 2024.
2. Return on assets (ROA) experienced significant variability, starting at 0.13% on December 31, 2020, jumping to 9.16% by December 31, 2021, and then fluctuating between 7.27% and 9.12% in the subsequent years. However, there was a notable decrease to 0.81% by December 31, 2024.
3. Return on total capital showed a substantial increase from 14.56% on December 31, 2020 to 44.05% by December 31, 2021, indicating strong capital efficiency. However, there were subsequent declines in the following years, with the ratio standing at 8.62% by December 31, 2024.
4. Return on equity (ROE) exhibited a similar pattern to ROA, with a significant rise from 0.49% on December 31, 2020 to 29.55% by December 31, 2021. The ratio then fluctuated between 21.65% and 24.81% in the subsequent years before dropping to 2.48% by December 31, 2024.
Overall, while some profitability ratios, such as Operating ROA and ROE, showed initial improvements and fluctuations, there were subsequent declines in these ratios by the end of the period. Return on total capital demonstrated a significant increase initially but also experienced a notable decrease over the years. The fluctuations in these ratios suggest potential operational and financial challenges faced by Gilead Sciences Inc in maintaining its profitability levels.